Vitamin D for Acute Intracerebral Hemorrhage
Key facts
- Who runs it
- The University of Hong Kong
- Where
- Hong Kong1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 1 Mar 2026
- Expected to end
- 28 Feb 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Vitamin D
- Record updated
- 6 May 2026
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Spontaneous ICH diagnosis
- Age ≥ 18 years
- Within 96 hours of ICH
- Premorbid Modified Rankin Scale of ≤2
- Supratentorial ICH
- ICH volume ≥2 mL
Who cannot take part
- Anticipated surgical evacuation of hematoma
- History of kidney stones
- Bleeding tendency
- Severe renal impairment
- Severe liver impairment
- Known contraindication or allergy to vitamin D
- Expected life expectancy of <1 year
- Glasgow Coma Scale <9
- Inability to participate in follow-up activity
- Hypercalcemia
- Hyperphosphatemia
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
This trial is currently available in Hong Kong.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Intracerebral hemorrhage (ICH) is the most deadly and debilitating form of stroke. To date, effective treatment that could improve the functional outcome of ICH remained elusive. In a mice model of ICH, it was demonstrated that high dose Vitamin D (VitD) treatment enhanced hematoma resolution by promoting reparative macrophage differentiation and improved neurobehavioral performance in mice. Hence, this pilot study aimed to investigate the feasibility and safety of VitD treatment for ICH in human subjects.
Read full original descriptionShow less
VICToHR is a prospective, randomized, open-label, blinded-endpoint (PROBE) trial. Participants will be randomized 1:1 to receive either VitD or standard care (control). The intervention group will receive VitD 4000 IU daily for 2 weeks, followed by 1000 IU daily for 24 weeks. The primary outcomes are the rate of hematoma resolution at 14 days and the incidence of hypercalcemia and VitD toxicity. Hematoma volume will be assessed by a neuroradiologist who is blinded to treatment allocation.
The 2 groups in the trial
- Vitamin D armExisting treatment, for comparison
Vitamin D 4000 IU daily for 2 weeks followed by 1000 IU for 24 weeks
Treatment: Vitamin D
- Control armNo study treatment, for comparison
No vitamin D
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Vitamin D Treatment in IntraCerebal Hemorrhage To Enhance Hematoma Resolution (VICToHR): a Pilot Study
- Criteria questions
- Built from NCT07458815, who can take part
- Record updated
- 6 May 2026